Theseus Pharmaceuticals reports Q4 EPS (35c), consensus (44c)

As of December 31, 2022, Theseus had cash, cash equivalents, and marketable securities of $211.8M vs. $244.7M as of December 31, 2021. Theseus expects current cash, cash equivalents, and marketable securities to fund operations and capital expenditures into 3Q25 based on its current operating plan. "2022 was a year of significant progress for Theseus across our growing pipeline. We initiated our first-in-human study for our lead candidate, THE-630, in advanced GIST; nominated THE-349 as the development candidate for our fourth-generation EGFR inhibitor program for patients with NSCLC; and made substantial progress across our discovery pipeline, culminating with the recent introduction of our third program, targeting BCR-ABL in patients with CML and Ph+ ALL," said CEO Tim Clackson. "With a strong cash runway, we are poised to continue executing in 2023 as we anticipate two clinical readouts from the ongoing dose-escalation study of THE-630, the IND filing for THE-349, and continued progress across our preclinical and discovery programs."